Shanghai Junshi Biosciences Co., Ltd. Class H (HK:1877)
:1877
Want to see HK:1877 full AI Analyst Report?
Top Page
Shanghai Junshi Biosciences Co., Ltd. Class H
(1877)
Select Model
Select Model
Rating:50Neutral
Price Target:
HK$23.00
â–Ľ(-16.49% Downside)
Action:Reiterated
Date:04/29/26
The score is held back primarily by weak financial performance—continued net losses and heavy cash burn despite strong gross margins and improving trends. Technicals are a clear positive, with the stock trading above major moving averages and positive MACD. Valuation is constrained by negative earnings (negative P/E) and no provided dividend yield.
Positive Factors
High gross margins
Sustained ~78.7% gross margins indicate strong product-level economics typical of biologics, giving the company durable pricing power and unit profitability. As fixed R&D and SG&A scale with sales, high gross margins materially improve the path to operating leverage and eventual profitability.
Negative Factors
Negative operating cash flow
Consistent negative operating and free cash flow indicate the business is burning cash and likely dependent on financing or partner milestones to fund operations. This weakens resilience to shocks, limits self-funded growth, and raises dilution or refinancing risk until operating cash flow turns positive.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins
Sustained ~78.7% gross margins indicate strong product-level economics typical of biologics, giving the company durable pricing power and unit profitability. As fixed R&D and SG&A scale with sales, high gross margins materially improve the path to operating leverage and eventual profitability.
Read all positive factors
Shanghai Junshi Biosciences Co., Ltd. Class H (1877) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$40.67B
Dividend YieldN/A
Average Volume (3M)7.63M
Price to Earnings (P/E)―
Beta (1Y)1.51
Revenue Growth34.19%
EPS Growth47.97%
CountryHK
Employees2,578
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.62
Shares Outstanding260,295,700
10 Day Avg. Volume5,398,960
30 Day Avg. Volume7,633,399
Financial Highlights & Ratios
PEG Ratio0.64
Price to Book (P/B)3.19
Price to Sales (P/S)7.92
P/FCF Ratio-15.87
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$32.17Price Target Upside16.80% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.44
Revenue Forecast (FY)HK$3.31B
Shanghai Junshi Biosciences Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in t...
How the Company Makes Money
Junshi Biosciences generates revenue primarily through (1) product sales of its commercialized drugs, where income is recognized from selling medicines to distributors, hospitals, pharmacies, and other healthcare channels (depending on the market ...
Shanghai Junshi Biosciences Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
56
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.71B | 2.43B | 1.95B | 1.50B | 1.45B | 4.02B |
| Gross Profit | 2.12B | 1.76B | 1.54B | 835.26M | 927.21M | 2.77B |
| EBITDA | -617.48M | -599.38M | -935.50M | -2.16B | -2.52B | -476.32M |
| Net Income | -655.78M | -851.76M | -1.28B | -2.28B | -2.39B | -718.56M |
Balance Sheet | ||||||
| Total Assets | 14.10B | 12.39B | 10.80B | 11.36B | 12.58B | 11.05B |
| Cash, Cash Equivalents and Short-Term Investments | 4.55B | 3.22B | 2.93B | 3.78B | 6.00B | 3.50B |
| Total Debt | 5.96B | 4.14B | 2.93B | 1.79B | 1.32B | 628.20M |
| Total Liabilities | 8.03B | 6.16B | 4.85B | 4.02B | 2.78B | 2.72B |
| Stockholders Equity | 5.88B | 6.03B | 5.86B | 7.17B | 9.50B | 7.96B |
Cash Flow | ||||||
| Free Cash Flow | -1.27B | -1.21B | -2.12B | -2.85B | -2.17B | -1.53B |
| Operating Cash Flow | -415.51M | -465.77M | -1.43B | -2.01B | -1.78B | -641.90M |
| Investing Cash Flow | -1.80B | -1.58B | -892.78M | -892.42M | -467.62M | -1.88B |
| Financing Cash Flow | 3.63B | 2.17B | 1.02B | 681.04M | 4.64B | 2.67B |
Shanghai Junshi Biosciences Co., Ltd. Class H Technical Analysis
Negative
27.54
Price Trends
24.17
Negative
23.10
Positive
25.71
Negative
Market Momentum
-0.45
Positive
45.43
Neutral
23.97
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1877, the sentiment is Negative. The current price of 27.54 is above the 20-day moving average (MA) of 25.05, above the 50-day MA of 24.17, and above the 200-day MA of 25.71, indicating a bearish trend. The MACD of -0.45 indicates Positive momentum. The RSI at 45.43 is Neutral, neither overbought nor oversold. The STOCH value of 23.97 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1877.
Shanghai Junshi Biosciences Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | HK$38.13B | 34.84 | 23.99% | ― | 16.65% | 0.87% | |
64 Neutral | HK$143.49B | 145.72 | 4.82% | ― | 38.55% | ― | |
56 Neutral | HK$67.60B | 36.25 | 32.32% | ― | 80.08% | ― | |
53 Neutral | HK$110.54B | -43.30 | -14.26% | ― | 44.03% | -108.83% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | HK$40.67B | -256.36 | -10.78% | ― | 34.19% | 47.97% | |
47 Neutral | HK$16.23B | -9.51 | -24.29% | ― | 8.50% | 35.24% |
* Healthcare Sector Average
HK:1877
Shanghai Junshi Biosciences Co., Ltd. Class H
23.16
6.60
39.86%
HK:1801
Innovent Biologics
80.95
22.35
38.14%
HK:9688
Zai Lab Ltd
14.69
-10.41
-41.47%
HK:9926
Akeso, Inc.
116.60
33.45
40.23%
HK:9995
RemeGen Co. Ltd. Class H
84.80
33.60
65.62%
HK:2696
Shanghai Henlius Biotech, Inc. Class H
70.75
28.65
68.05%
Shanghai Junshi Biosciences Co., Ltd. Class H Corporate Events
Junshi Wins NMPA Nod for Toripalimab Combo in First-Line HER2-Positive Urothelial Cancer
May 21, 2026
Shanghai Junshi Biosciences has received approval from China’s National Medical Products Administration for a supplemental new drug application expanding toripalimab’s use, in combination with RemeGen’s antibody-drug conjugate di...
Junshi Biosciences Launches 2026 A Share Employee Stock Ownership Scheme
Apr 27, 2026
Shanghai Junshi Biosciences has approved the adoption of a 2026 A Share Employee Stock Ownership Scheme aimed at aligning employee and shareholder interests, improving corporate governance, and enhancing staff cohesion and competitiveness. The sch...
Junshi Biosciences posts strong Q1 revenue growth and sharply reduced loss
Apr 27, 2026
Shanghai Junshi Biosciences has released an overseas regulatory announcement providing an English translation of its unaudited 2026 first-quarter financial report, prepared under PRC accounting standards for the STAR Market. The company reported o...
Junshi Biosciences Board Approves 2026 Q1 Report at Fully Attended Meeting
Apr 27, 2026
Shanghai Junshi Biosciences Co., Ltd. has disclosed an overseas regulatory announcement in Hong Kong, aligning its Hong Kong disclosure with information released on the Shanghai Stock Exchange. The notice reiterates the company’s compliance ...
Junshi Biosciences Shareholder Plans Up to 2% Stake Reduction
Apr 23, 2026
Shanghai Junshi Biosciences announced that shareholder Shanghai Tanying Investment Partnership (LP), a private equity fund and pre-IPO investor, currently holds 59,459,326 A shares, representing 5.7914% of the company’s total share capital, ...
Junshi Biosciences Adds Subsidiary to Lead Key Innovative Drug R&D Projects
Apr 21, 2026
Shanghai Junshi Biosciences Co., Ltd. has designated its wholly owned subsidiary Ningbo Junyan Hongshi Biomedical Technology Co., Ltd. as an additional implementing entity for certain sub-projects within its innovative drug RD investment program, ...
Shanghai Junshi Biosciences Sets Board Meeting to Approve Q1 2026 Results
Apr 15, 2026
Shanghai Junshi Biosciences Co., Ltd. has scheduled a board meeting for April 27, 2026, to review and approve the group’s unaudited financial results for the three months ended March 31, 2026. The announcement signals the upcoming release of...
Junshi Biosciences’ Major Shareholder Lets Share-Sale Plan Expire Unused
Apr 10, 2026
Shanghai Junshi Biosciences has announced that a planned shareholding reduction by substantial shareholder Shanghai Tanying Investment Partnership (LP), which held 5.79% of the company’s total share capital in A shares, has reached its expir...
Junshi Biosciences Chairman Completes RMB100 Million Shareholding Increase
Mar 31, 2026
Shanghai Junshi Biosciences has disclosed that its chairman, controlling shareholder and actual controller, Xiong Jun, has completed a planned increase in his holdings of both A shares and H shares of the company. The plan, launched on 12 April 20...
Shanghai Junshi Biosciences Schedules 2025 Results Briefing for Investor Q&A
Mar 20, 2026
Shanghai Junshi Biosciences Co., Ltd. has announced plans to hold its 2025 annual results briefing, following the disclosure of its 2025 annual report on the Shanghai Stock Exchange website on 14 March 2026. The online briefing will be held via th...
Junshi Biosciences Chairman Continues Shareholding Increase Plan
Mar 16, 2026
Shanghai Junshi Biosciences announced the latest progress of a previously disclosed plan by chairman and controlling shareholder Xiong Jun to increase his holdings in the company’s A and H shares by at least RMB100 million over a 12‑mo...
Junshi Biosciences Board Approves 2025 Work Report and Highlights Governance Actions
Mar 13, 2026
Shanghai Junshi Biosciences Co., Ltd. has reported that its seventeenth meeting of the fourth session of the board of directors was duly convened on 13 March 2026, with all 14 eligible directors in attendance and procedures confirmed as compliant ...
Shanghai Junshi Biosciences Details Board and Committee Structure
Mar 13, 2026
Shanghai Junshi Biosciences Co., Ltd. has announced the current composition of its board of directors, which includes a mix of executive, non-executive and independent non-executive directors, led by chairman and legal representative Xiong Jun. Th...
Shanghai Junshi Biosciences Sets Terms for New Strategic and ESG Board Committee
Mar 13, 2026
Shanghai Junshi Biosciences Co., Ltd. has established a Strategic and ESG Committee under its board of directors, formalizing the committee’s terms of reference to guide its structure and operations. The document outlines the committee’...
Junshi Biosciences Adds ESG Focus and Revamps Pay Policies
Mar 13, 2026
Shanghai Junshi Biosciences has upgraded its board-level strategic committee into a Strategic and ESG Committee, expanding its remit to cover environmental, social and governance issues alongside long-term strategy and major investments. The move ...
Shanghai Junshi Biosciences Lifts Revenue and Narrows Loss as Immuno-Oncology Pipeline Advances
Mar 13, 2026
Shanghai Junshi Biosciences reported a 28% rise in 2025 revenue to about RMB2.5 billion, driven mainly by a 38% surge in domestic sales of its core PD-1 antibody TUOYI, while RD spending rose 9% to RMB1.38 billion as the company pushed more compet...
Junshi Biosciences Details Use and Return of Idle Fundraising Proceeds for Liquidity
Mar 12, 2026
Shanghai Junshi Biosciences has disclosed that it previously obtained board approval to use up to RMB2 billion of idle fundraising proceeds to temporarily supplement working capital for up to 12 months. The funds were restricted to business expans...
Junshi Biosciences Chairman Continues Incremental Share Purchase Plan
Mar 10, 2026
Shanghai Junshi Biosciences has disclosed progress on a previously announced plan by chairman and controlling shareholder Xiong Jun to increase his holdings in the company’s A and H shares by at least RMB100 million over a 12‑month per...
Junshi Biosciences’ Subcutaneous Toripalimab NDAs Accepted in China
Mar 9, 2026
Shanghai Junshi Biosciences has received acceptance from China’s National Medical Products Administration for new drug applications covering 12 tumor-related indications of its toripalimab subcutaneous injection, JS001sc. The formulation is ...
Shanghai Junshi Biosciences Sets March 2026 Board Meeting to Approve 2025 Results
Mar 2, 2026
Shanghai Junshi Biosciences Co., Ltd. has scheduled a board meeting for 13 March 2026 to review and approve the group’s final results for the financial year ended 31 December 2025. The board will also consider whether to recommend a final di...
Junshi Biosciences Narrows 2025 Loss as Revenue Climbs Nearly 30%
Feb 27, 2026
Shanghai Junshi Biosciences Co., Ltd., a China-based biopharmaceutical developer of innovative antibody drugs and other advanced therapies, operates in the competitive global healthcare market with a focus on major disease areas. The company is li...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.